GSK plc
LSEGSK delivered its Q2 results on July 29 and the post-print picture looks materially different from the cautious setup that preceded it. The most striking data shift this week is the ORTEX short score, which collapsed from 37.1 on July 27 to 26.2 by July 30 — a ten-point drop in three sessions. That move puts the score firmly in the lower third of the scale and signals that the…
Snapshot as of 6 Aug 2026
GSK delivered its Q2 results on July 29 and the post-print picture looks materially different from the cautious setup that preceded it. The most striking data shift this week is the ORTEX short score, which collapsed…
GSK reports Q2 results on July 28 against an awkward backdrop: the stock is down 1.4% on the week while close pharma peers have moved sharply higher, leaving GSK as the relative laggard heading into the print. The peer…
GSK has spent the past week largely treading water while close peers caught up — the setup heading into a July 28 earnings date is one of converging price action, an ebbing short score, and a Street that remains…
GSK is the quiet outperformer in a difficult week for large-cap pharma — up 2.4% while most of its closest peers fell — and the question worth sitting with is whether that relative strength reflects genuine conviction…
GSK heads into its July 28 Q2 results on a quiet improving trend — shares up 3% this week and 4.4% over the past month, while short sellers have reduced positions to their smallest level in over six weeks. The most…
GSK enters its Q1 2026 results on April 29 carrying a stock down 6% on the week and a short book that has quietly unwound heading into the print. The most telling positioning signal is how dramatically short sellers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GSK — free to start on ORTEX.
Sign up for free →Open GSK on ORTEX